Tumor Suppressor Proteins
"Tumor Suppressor Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
| Descriptor ID |
D025521
|
| MeSH Number(s) |
D12.776.624.776
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Proteins".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Proteins".
This graph shows the total number of publications written about "Tumor Suppressor Proteins" by people in this website by year, and whether "Tumor Suppressor Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 4 | 5 |
| 1995 | 4 | 3 | 7 |
| 1996 | 3 | 5 | 8 |
| 1997 | 7 | 3 | 10 |
| 1998 | 18 | 8 | 26 |
| 1999 | 27 | 8 | 35 |
| 2000 | 15 | 9 | 24 |
| 2001 | 27 | 17 | 44 |
| 2002 | 27 | 29 | 56 |
| 2003 | 28 | 31 | 59 |
| 2004 | 24 | 48 | 72 |
| 2005 | 35 | 39 | 74 |
| 2006 | 29 | 13 | 42 |
| 2007 | 35 | 27 | 62 |
| 2008 | 40 | 15 | 55 |
| 2009 | 29 | 12 | 41 |
| 2010 | 31 | 27 | 58 |
| 2011 | 36 | 18 | 54 |
| 2012 | 32 | 15 | 47 |
| 2013 | 38 | 15 | 53 |
| 2014 | 24 | 19 | 43 |
| 2015 | 12 | 18 | 30 |
| 2016 | 24 | 12 | 36 |
| 2017 | 11 | 8 | 19 |
| 2018 | 16 | 8 | 24 |
| 2019 | 14 | 8 | 22 |
| 2020 | 14 | 7 | 21 |
| 2021 | 7 | 12 | 19 |
| 2022 | 4 | 10 | 14 |
| 2023 | 2 | 5 | 7 |
| 2024 | 3 | 9 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Proteins" by people in Profiles.
-
WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy. J Immunother Cancer. 2024 Nov 05; 12(11).
-
The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia. Blood Cancer J. 2024 10 23; 14(1):168.
-
Temozolomide use in elderly patients with MGMT promoter unmethylated glioblastoma: Is it finally time to dismount a dead horse? Neuro Oncol. 2024 Oct 03; 26(10):1876-1877.
-
Prognostic Impact of Notch1 Intracellular Domain, P63, and c-MYC in Lacrimal Gland Adenoid Cystic Carcinoma. Invest Ophthalmol Vis Sci. 2024 Sep 03; 65(11):4.
-
COMPREHENSIVE MOLECULAR PROFILING OF UVEAL MELANOMA EVALUATED WITH GENE EXPRESSION PROFILING, PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA EXPRESSION, AND NEXT-GENERATION SEQUENCING. Retina. 2024 09 01; 44(9):1580-1589.
-
BCR::ZNF711 and BCR::CYLC2 Fusions: Novel BCR Fusions Expanding the Molecular Spectrum of Gene Fusions in Melanoma. Am J Dermatopathol. 2024 Nov 01; 46(11):797-799.
-
Interaction between MED12 and ?Np63 activates basal identity in pancreatic ductal adenocarcinoma. Nat Genet. 2024 Jul; 56(7):1377-1385.
-
Low NDRG2, regulated by the MYC/MIZ-1 complex and methylation, predicts poor outcomes in DLBCL patients. Ann Hematol. 2024 Aug; 103(8):2877-2892.
-
GZ17-6.02 kills PDX isolates of uveal melanoma. Oncotarget. 2024 May 17; 15:328-344.
-
Utility of next-generation sequencing in the diagnosis of metastatic melanoma: A case report. J Cutan Pathol. 2024 Sep; 51(9):644-648.